Posted by Michael Wonder on 12 Jan 2016
Eisai submits new drug application in Europe for in-house developed anti-cancer agent lenvatinib seeking approval for indication covering renal cell carcinoma
12 January 2016 - As a new medicine that is expected to be of major public health interest, particularly from the viewpoint of therapeutic innovation, lenvatinib has been granted an accelerated review by the EMA.
For more details, go to: http://www.eisai.com/news/news201602.html
